PedAM

Pediatric Disease Annotations & Medicines


	thrombocytopenia

Disease ID	124
Disease	thrombocytopenia
Definition	A subnormal level of BLOOD PLATELETS.
Synonym	platelet count decreased thrombocytopaenia thrombocytopenia (disorder) thrombocytopenia [disease/finding] thrombocytopenia nos thrombocytopenia nos (disorder) thrombocytopenia, nos thrombocytopenia, unspecified thrombocytopenias thrombocytopenic disorder thrombocytopenic disorder (disorder) thrombopenia thrombopenias
DOID	DOID:1588
ICD10	ICD10CM:D69.6
UMLS	C0040034
MeSH	D013921
SNOMED-CT	SNOMEDCT_US_2016_09_01:302215000
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:262) C0002871 \| anemia \| 76 C0040053 \| thrombosis \| 42 C0019158 \| hepatitis \| 35 C0002878 \| hemolytic anemia \| 30 C0027947 \| neutropenia \| 29 C0019196 \| hepatitis c \| 25 C0023895 \| liver disease \| 22 C0023890 \| cirrhosis \| 19 C0024530 \| malaria \| 18 C0024141 \| systemic lupus erythematosus \| 16 C0020532 \| hypersplenism \| 14 C0409974 \| lupus erythematosus \| 13 C0023418 \| leukemia \| 13 C0002871 \| anaemia \| 11 C0026986 \| myelodysplastic syndrome \| 10 C0023890 \| liver cirrhosis \| 9 C0042769 \| virus infection \| 9 C0034150 \| purpura \| 9 C0023530 \| leucopenia \| 9 C0155765 \| microangiopathy \| 8 C0007102 \| colon cancer \| 7 C0023530 \| leukopenia \| 7 C0272286 \| immune thrombocytopenia \| 6 C0041296 \| tuberculosis \| 6 C0030312 \| pancytopenia \| 6 C0017205 \| gaucher disease \| 5 C0019100 \| dengue hemorrhagic fever \| 5 C0023364 \| leptospirosis \| 5 C0034065 \| pulmonary embolism \| 5 C0035078 \| renal failure \| 5 C0026986 \| myelodysplastic syndromes \| 5 C0030312 \| bone marrow failure \| 4 C0020541 \| portal hypertension \| 4 C0034155 \| thrombotic thrombocytopenic purpura \| 4 C0011847 \| diabetes \| 4 C0023434 \| chronic lymphocytic leukemia \| 4 C0020538 \| hypertension \| 4 C0002878 \| haemolytic anaemia \| 4 C0032285 \| pneumonia \| 4 C0024537 \| vivax malaria \| 4 C0042769 \| viral infection \| 4 C0024537 \| plasmodium vivax malaria \| 4 C0024535 \| falciparum malaria \| 4 C0836924 \| thrombocytosis \| 3 C0015230 \| rash \| 3 C0085278 \| antiphospholipid syndrome \| 3 C0032914 \| preeclampsia \| 3 C0041327 \| pulmonary tuberculosis \| 3 C0162316 \| iron deficiency anemia \| 3 C0024299 \| lymphoma \| 3 C0014867 \| esophageal varices \| 3 C0023895 \| liver diseases \| 3 C0241910 \| autoimmune hepatitis \| 3 C0002880 \| autoimmune hemolytic anemia \| 3 C0085669 \| acute leukemia \| 3 C0012739 \| disseminated intravascular coagulation \| 3 C0598894 \| monocytic leukemia \| 3 C0042345 \| varices \| 3 C1260402 \| splenic sequestration \| 3 C0024312 \| lymphopenia \| 3 C0001824 \| agranulocytosis \| 3 C1565489 \| renal insufficiency \| 3 C0040053 \| thrombus \| 3 C0023448 \| lymphocytic leukemia \| 3 C0002880 \| autoimmune haemolytic anaemia \| 2 C0027051 \| myocardial infarct \| 2 C0006309 \| brucellosis \| 2 C0024623 \| gastric cancer \| 2 C0023418 \| leukemias \| 2 C0376545 \| hematologic malignancies \| 2 C0010346 \| crohn's disease \| 2 C0027051 \| myocardial infarction \| 2 C0010068 \| coronary artery disease \| 2 C0019099 \| crimean-congo hemorrhagic fever \| 2 C0019061 \| hemolytic uremic syndrome \| 2 C0018916 \| hemangiomas \| 2 C0033687 \| proteinuria \| 2 C0012739 \| disseminated intravascular coagulation (dic) \| 2 C0007570 \| celiac disease \| 2 C0013595 \| eczema \| 2 C0040028 \| essential thrombocythemia \| 2 C0007785 \| cerebral infarct \| 2 C0009402 \| colorectal cancer \| 2 C0019087 \| hemorrhagic diathesis \| 2 C0012739 \| consumption coagulopathy \| 2 C0026764 \| multiple myeloma \| 2 C0023449 \| acute lymphoblastic leukaemia \| 2 C0012739 \| consumptive coagulopathy \| 2 C0011854 \| type 1 diabetes \| 2 C0043117 \| idiopathic thrombocytopenic purpura \| 2 C0043194 \| wiskott-aldrich syndrome \| 2 C0039730 \| thalassemia \| 2 C0341858 \| adenomyosis \| 2 C0021400 \| influenza \| 2 C0019196 \| hepatitis c infection \| 2 C0007785 \| cerebral infarction \| 2 C0011570 \| depression \| 2 C0042769 \| viral infections \| 2 C0007113 \| rectal cancer \| 2 C0008049 \| varicella \| 2 C0242584 \| autoimmune thrombocytopenia \| 1 C0034188 \| xanthogranulomatous pyelonephritis \| 1 C0033860 \| psoriasis \| 1 C0041227 \| trypanosomosis \| 1 C0032285 \| lung inflammation \| 1 C0403447 \| chronic renal insufficiency \| 1 C0042721 \| viral hepatitis \| 1 C0856761 \| budd-chiari syndrome \| 1 C0017636 \| glioblastoma \| 1 C1261473 \| sarcoma \| 1 C0023467 \| acute myelogenous leukemia \| 1 C0001623 \| adrenal insufficiency \| 1 C0020459 \| hyperinsulinism \| 1 C1955861 \| t-lgl leukemia \| 1 C0026764 \| myeloma \| 1 C0009447 \| common variable immunodeficiency \| 1 C0376358 \| prostate cancer \| 1 C0405580 \| hypoadrenocorticism \| 1 C0024419 \| macroglobulinemia \| 1 C0041321 \| miliary tuberculosis \| 1 C1140680 \| ovarian cancer \| 1 C0086543 \| cataract \| 1 C0024299 \| malignant lymphoma \| 1 C0015530 \| factor xiii deficiency \| 1 C0019829 \| hodgkin lymphoma \| 1 C0036323 \| schistosomiasis \| 1 C0021053 \| immune disorders \| 1 C0685938 \| gastrointestinal cancer \| 1 C0152025 \| polyneuropathy \| 1 C0026654 \| moyamoya \| 1 C0042384 \| vasculitis \| 1 C0007115 \| thyroid cancer \| 1 C0278883 \| metastatic melanoma \| 1 C0004576 \| babesiosis \| 1 C0031347 \| pharyngeal cancer \| 1 C0027022 \| myeloproliferative disorders \| 1 C0007115 \| thyroid ca \| 1 C0022661 \| chronic renal failure \| 1 C0006663 \| calcinosis \| 1 C0272236 \| hyper-igm syndrome \| 1 C0242379 \| lung cancer \| 1 C0023788 \| whipple's disease \| 1 C0398623 \| hypercoagulability state \| 1 C0034186 \| pyelonephritis \| 1 C0020538 \| hypertensive disease \| 1 C0010414 \| cryptococcosis \| 1 C0032302 \| mycoplasma pneumonia \| 1 C0017601 \| glaucoma \| 1 C0011880 \| diabetic ketoacidosis \| 1 C0020302 \| congenital glaucoma \| 1 C0270922 \| demyelinating polyneuropathy \| 1 C0022661 \| end-stage renal failure \| 1 C0022658 \| renal disorders \| 1 C0008312 \| primary biliary cirrhosis \| 1 C0019204 \| hepatocellular carcinoma \| 1 C0024419 \| waldenstrom's macroglobulinemia \| 1 C0018920 \| cavernous hemangioma \| 1 C0032001 \| pituitary apoplexy \| 1 C0043117 \| immune thrombocytopenic purpura \| 1 C0018920 \| cavernous hemangiomas \| 1 C0027121 \| myositis \| 1 C0011603 \| dermatitis \| 1 C0008312 \| biliary cirrhosis \| 1 C0393819 \| chronic inflammatory demyelinating polyneuropathy \| 1 C0034063 \| pulmonary edema \| 1 C0041331 \| splenic tuberculosis \| 1 C0158761 \| radioulnar synostosis \| 1 C0006060 \| boutonneuse fever \| 1 C0009782 \| connective tissue diseases \| 1 C0018818 \| ventricular septal defect \| 1 C0022354 \| cholestatic jaundice \| 1 C0027697 \| nephritis \| 1 C0008049 \| varicella infection \| 1 C0036421 \| systemic sclerosis \| 1 C0018916 \| angioma \| 1 C0000832 \| placental abruption \| 1 C0024115 \| lung disease \| 1 C0019101 \| hemorrhagic fever with renal syndrome \| 1 C0040100 \| thymoma \| 1 C0555198 \| malignant glioma \| 1 C0023418 \| leukaemia \| 1 C0085576 \| microcytic anemia \| 1 C0085278 \| anti-phospholipid syndrome \| 1 C0085399 \| ehrlichiosis \| 1 C0029463 \| osteosarcoma \| 1 C0003864 \| arthritis \| 1 C0007642 \| cellulitis \| 1 C0026934 \| mycoplasma \| 1 C1704437 \| respiratory distress syndrome \| 1 C0021053 \| immune disease \| 1 C0019202 \| wilson disease \| 1 C0025362 \| mental retardation \| 1 C0018784 \| sensorineural hearing loss \| 1 C1145670 \| respiratory failure \| 1 C0029456 \| osteoporosis \| 1 C0272302 \| gray platelet syndrome \| 1 C0022660 \| acute renal failure \| 1 C0011991 \| diarrhea \| 1 C0009782 \| connective tissue disease \| 1 C0042769 \| viral disease \| 1 C0021053 \| immune disorder \| 1 C0013592 \| ectropion \| 1 C0014038 \| encephalitis \| 1 C0019163 \| hepatitis b \| 1 C0033117 \| priapism \| 1 C0037354 \| smallpox \| 1 C0001418 \| adenocarcinoma \| 1 C0276688 \| pulmonary cryptococcosis \| 1 C0035309 \| retinopathy \| 1 C0038012 \| spondylitis \| 1 C0014867 \| oesophageal varices \| 1 C0025309 \| meningoencephalitis \| 1 C0024419 \| waldenstrom macroglobulinemia \| 1 C0152021 \| congenital heart disease \| 1 C0023449 \| acute lymphoblastic leukemia \| 1 C0023448 \| lymphoblastic leukemia \| 1 C0175703 \| tar syndrome \| 1 C0002892 \| pernicious anemia \| 1 C0015625 \| fanconi anemia \| 1 C0398623 \| hypercoagulability \| 1 C0079731 \| b-cell lymphoma \| 1 C0376300 \| dengue shock syndrome \| 1 C0023891 \| alcoholic cirrhosis \| 1 C0087086 \| thrombi \| 1 C0036202 \| sarcoidosis \| 1 C0023470 \| myelogenous leukemia \| 1 C0376545 \| hematologic malignancy \| 1 C0334634 \| mantle cell lymphoma \| 1 C0085293 \| hepatitis e \| 1 C0085692 \| hemorrhagic cystitis \| 1 C0040188 \| tic disorders \| 1 C0035222 \| acute respiratory distress syndrome \| 1 C0027059 \| myocarditis \| 1 C0041466 \| typhoid \| 1 C0027022 \| myeloproliferative disorder \| 1 C0206062 \| interstitial lung disease \| 1 C0001403 \| addison's disease \| 1 C0026654 \| moyamoya disease \| 1 C0025303 \| meningococcal disease \| 1 C0153392 \| nasopharyngeal cancer \| 1 C0024790 \| paroxysmal nocturnal hemoglobinuria \| 1 C0085278 \| anti-phospholipid antibody syndrome \| 1 C0272126 \| evan's syndrome \| 1 C0398689 \| x-linked hyper-igm syndrome \| 1 C0039538 \| teratoma \| 1 C0024534 \| cerebral malaria \| 1 C0004626 \| bacterial pneumonia \| 1 C0010072 \| coronary thrombosis \| 1 C1140680 \| ovarian ca \| 1 C0011633 \| dermatomyositis \| 1 C0010692 \| cystitis \| 1 C0024299 \| lymphomas \| 1 C0001815 \| myelofibrosis \| 1 C0272126 \| evans' syndrome \| 1 C0009324 \| ulcerative colitis \| 1 C0024305 \| non-hodgkin lymphoma \| 1 C0038013 \| ankylosing spondylitis \| 1 C0149931 \| migraine \| 1 C0041327 \| pulmonary tb \| 1 C0002886 \| macrocytic anemia \| 1 C0003507 \| aortic valve stenosis \| 1 C0004045 \| birth asphyxia \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:23) PECAM1 \| 5175 \| CTD_human ITGB3 \| 3690 \| CTD_human XDH \| 7498 \| CTD_human FCGR2A \| 2212 \| CTD_human CSF2 \| 1437 \| CTD_human ALB \| 213 \| CTD_human IFNA2 \| 3440 \| CTD_human GP9 \| 2815 \| CTD_human MTHFR \| 4524 \| CTD_human CSF3 \| 1440 \| CTD_human EPO \| 2056 \| CTD_human TNFRSF10A \| 8797 \| CTD_human PF4 \| 5196 \| CTD_human ETV6 \| 2120 \| CLINVAR;CTD_human GP1BB \| 2812 \| CTD_human ASPG \| 374569 \| CTD_human CYCS \| 54205 \| CTD_human ITPA \| 3704 \| CTD_human ITGA2B \| 3674 \| CTD_human HLA-A \| 3105 \| CTD_human WDR1 \| 9948 \| CTD_human GATA1 \| 2623 \| CTD_human IL3 \| 3562 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:18) 54205 \| CYCS \| infer 2147 \| F2 \| infer 2153 \| F5 \| infer 355 \| FAS \| infer 356 \| FASLG \| infer 2212 \| FCGR2A \| infer 2214 \| FCGR3A \| infer 2811 \| GP1BA \| infer 2812 \| GP1BB \| infer 2814 \| GP5 \| infer 2815 \| GP9 \| infer 3125 \| HLA-DRB3 \| infer 3673 \| ITGA2 \| infer 3674 \| ITGA2B \| infer 3690 \| ITGB3 \| infer 4524 \| MTHFR \| infer 4627 \| MYH9 \| infer 26191 \| PTPN22 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:556) 104940698 \| DALIR \| DISEASES 100302690 \| DLG2-AS1 \| DISEASES 381 \| ARF5 \| DISEASES 3207 \| HOXA11 \| DISEASES 928 \| CD9 \| DISEASES 920 \| CD4 \| DISEASES 2067 \| ERCC1 \| DISEASES 933 \| CD22 \| DISEASES 3385 \| ICAM3 \| DISEASES 2249 \| FGF4 \| DISEASES 30009 \| TBX21 \| DISEASES 1361 \| CPB2 \| DISEASES 7066 \| THPO \| DISEASES 350 \| APOH \| DISEASES 201294 \| UNC13D \| DISEASES 3053 \| SERPIND1 \| DISEASES 402055 \| SRRD \| DISEASES 9567 \| GTPBP1 \| DISEASES 4627 \| MYH9 \| DISEASES 3002 \| GZMB \| DISEASES 5875 \| RABGGTA \| DISEASES 6790 \| AURKA \| DISEASES 10544 \| PROCR \| DISEASES 81027 \| TUBB1 \| DISEASES 9352 \| TXNL1 \| DISEASES 2158 \| F9 \| DISEASES 479 \| ATP12A \| DISEASES 54 \| ACP5 \| DISEASES 10273 \| STUB1 \| DISEASES 5327 \| PLAT \| DISEASES 8797 \| TNFRSF10A \| DISEASES 64130 \| LIN7B \| DISEASES 2217 \| FCGRT \| DISEASES 10535 \| RNASEH2A \| DISEASES 2091 \| FBL \| DISEASES 7040 \| TGFB1 \| DISEASES 973 \| CD79A \| DISEASES 1048 \| CEACAM5 \| DISEASES 51678 \| MPP6 \| DISEASES 6804 \| STX1A \| DISEASES 8976 \| WASL \| DISEASES 5054 \| SERPINE1 \| DISEASES 727 \| C5 \| DISEASES 4353 \| MPO \| DISEASES 1440 \| CSF3 \| DISEASES 9144 \| SYNGR2 \| DISEASES 6347 \| CCL2 \| DISEASES 6346 \| CCL1 \| DISEASES 7448 \| VTN \| DISEASES 952 \| CD38 \| DISEASES 5197 \| PF4V1 \| DISEASES 3558 \| IL2 \| DISEASES 81622 \| UNC93B1 \| DISEASES 595 \| CCND1 \| DISEASES 4254 \| KITLG \| DISEASES 3458 \| IFNG \| DISEASES 55907 \| CMAS \| DISEASES 3565 \| IL4 \| DISEASES 5917 \| RARS \| DISEASES 604 \| BCL6 \| DISEASES 10289 \| EIF1B \| DISEASES 7035 \| TFPI \| DISEASES 374291 \| NDUFS7 \| DISEASES 566 \| AZU1 \| DISEASES 23178 \| PASK \| DISEASES 5341 \| PLEK \| DISEASES 6402 \| SELL \| DISEASES 4317 \| MMP8 \| DISEASES 9429 \| ABCG2 \| DISEASES 5217 \| PFN2 \| DISEASES 9479 \| MAPK8IP1 \| DISEASES 51426 \| POLK \| DISEASES 2322 \| FLT3 \| DISEASES 79441 \| HAUS3 \| DISEASES 1088 \| CEACAM8 \| DISEASES 55831 \| EMC3 \| DISEASES 4620 \| MYH2 \| DISEASES 718 \| C3 \| DISEASES 8698 \| S1PR4 \| DISEASES 826 \| CAPNS1 \| DISEASES 51119 \| SBDS \| DISEASES 6945 \| MLX \| DISEASES 7277 \| TUBA4A \| DISEASES 2678 \| GGT1 \| DISEASES 3976 \| LIF \| DISEASES 968 \| CD68 \| DISEASES 6351 \| CCL4 \| DISEASES 599 \| BCL2L2 \| DISEASES 25943 \| C20orf194 \| DISEASES 4695 \| NDUFA2 \| DISEASES 84262 \| PSMG3 \| DISEASES 10912 \| GADD45G \| DISEASES 2056 \| EPO \| DISEASES 51659 \| GINS2 \| DISEASES 2161 \| F12 \| DISEASES 47 \| ACLY \| DISEASES 5914 \| RARA \| DISEASES 6382 \| SDC1 \| DISEASES 6737 \| TRIM21 \| DISEASES 1401 \| CRP \| DISEASES 3845 \| KRAS \| DISEASES 10894 \| LYVE1 \| DISEASES 2694 \| GIF \| DISEASES 5156 \| PDGFRA \| DISEASES 967 \| CD63 \| DISEASES 10200 \| MPHOSPH6 \| DISEASES 3569 \| IL6 \| DISEASES 1101 \| CHAD \| DISEASES 3557 \| IL1RN \| DISEASES 7097 \| TLR2 \| DISEASES 25833 \| POU2F3 \| DISEASES 7057 \| THBS1 \| DISEASES 6496 \| SIX3 \| DISEASES 6741 \| SSB \| DISEASES 9360 \| PPIG \| DISEASES 3417 \| IDH1 \| DISEASES 3685 \| ITGAV \| DISEASES 4069 \| LYZ \| DISEASES 7450 \| VWF \| DISEASES 55012 \| PPP2R3C \| DISEASES 23495 \| TNFRSF13B \| DISEASES 5159 \| PDGFRB \| DISEASES 3690 \| ITGB3 \| DISEASES 9172 \| MYOM2 \| DISEASES 945 \| CD33 \| DISEASES 4591 \| TRIM37 \| DISEASES 3674 \| ITGA2B \| DISEASES 495 \| ATP4A \| DISEASES 25939 \| SAMHD1 \| DISEASES 3682 \| ITGAE \| DISEASES 23523 \| CABIN1 \| DISEASES 3552 \| IL1A \| DISEASES 3553 \| IL1B \| DISEASES 6403 \| SELP \| DISEASES 55850 \| USE1 \| DISEASES 3791 \| KDR \| DISEASES 943 \| TNFRSF8 \| DISEASES 1001 \| CDH3 \| DISEASES 60482 \| SLC5A7 \| DISEASES 941 \| CD80 \| DISEASES 59067 \| IL21 \| DISEASES 2247 \| FGF2 \| DISEASES 3589 \| IL11 \| DISEASES 22794 \| CASC3 \| DISEASES 6774 \| STAT3 \| DISEASES 2122 \| MECOM \| DISEASES 5443 \| POMC \| DISEASES 7297 \| TYK2 \| DISEASES 3383 \| ICAM1 \| DISEASES 950 \| SCARB2 \| DISEASES 7535 \| ZAP70 \| DISEASES 3827 \| KNG1 \| DISEASES 2028 \| ENPEP \| DISEASES 4986 \| OPRK1 \| DISEASES 10312 \| TCIRG1 \| DISEASES 5243 \| ABCB1 \| DISEASES 6717 \| SRI \| DISEASES 5286 \| PIK3C2A \| DISEASES 3700 \| ITIH4 \| DISEASES 3480 \| IGF1R \| DISEASES 10066 \| SCAMP2 \| DISEASES 8128 \| ST8SIA2 \| DISEASES 5373 \| PMM2 \| DISEASES 3687 \| ITGAX \| DISEASES 1039 \| CDR2 \| DISEASES 92579 \| G6PC3 \| DISEASES 4628 \| MYH10 \| DISEASES 432 \| ASGR1 \| DISEASES 7157 \| TP53 \| DISEASES 2064 \| ERBB2 \| DISEASES 5678 \| PSG9 \| DISEASES 3454 \| IFNAR1 \| DISEASES 150094 \| SIK1 \| DISEASES 207 \| AKT1 \| DISEASES 2212 \| FCGR2A \| DISEASES 64241 \| ABCG8 \| DISEASES 3578 \| IL9 \| DISEASES 1956 \| EGFR \| DISEASES 2041 \| EPHA1 \| DISEASES 3439 \| IFNA1 \| DISEASES 90952 \| ESAM \| DISEASES 10398 \| MYL9 \| DISEASES 3606 \| IL18 \| DISEASES 5805 \| PTS \| DISEASES 925 \| CD8A \| DISEASES 8526 \| DGKE \| DISEASES 84959 \| UBASH3B \| DISEASES 1436 \| CSF1R \| DISEASES 27163 \| NAAA \| DISEASES 9154 \| SLC28A1 \| DISEASES 135228 \| CD109 \| DISEASES 6750 \| SST \| DISEASES 3815 \| KIT \| DISEASES 2207 \| FCER1G \| DISEASES 27020 \| NPTN \| DISEASES 11189 \| CELF3 \| DISEASES 197131 \| UBR1 \| DISEASES 1636 \| ACE \| DISEASES 115650 \| TNFRSF13C \| DISEASES 5739 \| PTGIR \| DISEASES 7307 \| U2AF1 \| DISEASES 115653 \| KIR3DL3 \| DISEASES 114757 \| CYGB \| DISEASES 56344 \| CABP5 \| DISEASES 6352 \| CCL5 \| DISEASES 3889 \| KRT83 \| DISEASES 6006 \| RHCE \| DISEASES 126820 \| WDR63 \| DISEASES 7412 \| VCAM1 \| DISEASES 2215 \| FCGR3B \| DISEASES 64320 \| RNF25 \| DISEASES 213 \| ALB \| DISEASES 6374 \| CXCL5 \| DISEASES 5473 \| PPBP \| DISEASES 5196 \| PF4 \| DISEASES 308 \| ANXA5 \| DISEASES 3673 \| ITGA2 \| DISEASES 4724 \| NDUFS4 \| DISEASES 3562 \| IL3 \| DISEASES 1437 \| CSF2 \| DISEASES 819 \| CAMLG \| DISEASES 57094 \| CPA6 \| DISEASES 51266 \| CLEC1B \| DISEASES 201161 \| CENPV \| DISEASES 290 \| ANPEP \| DISEASES 5347 \| PLK1 \| DISEASES 219983 \| OR4D6 \| DISEASES 861 \| RUNX1 \| DISEASES 90678 \| LRSAM1 \| DISEASES 6786 \| STIM1 \| DISEASES 4255 \| MGMT \| DISEASES 598 \| BCL2L1 \| DISEASES 10296 \| MAEA \| DISEASES 143501 \| C11orf40 \| DISEASES 54578 \| UGT1A6 \| DISEASES 43 \| ACHE \| DISEASES 613 \| BCR \| DISEASES 1493 \| CTLA4 \| DISEASES 2815 \| GP9 \| DISEASES 171558 \| PTCRA \| DISEASES 54658 \| UGT1A1 \| DISEASES 3627 \| CXCL10 \| DISEASES 25998 \| IBTK \| DISEASES 4135 \| MAP6 \| DISEASES 64805 \| P2RY12 \| DISEASES 4632 \| MYL1 \| DISEASES 54205 \| CYCS \| DISEASES 27087 \| B3GAT1 \| DISEASES 695 \| BTK \| DISEASES 2147 \| F2 \| DISEASES 29984 \| RHOD \| DISEASES 51206 \| GP6 \| DISEASES 5340 \| PLG \| DISEASES 1212 \| CLTB \| DISEASES 7015 \| TERT \| DISEASES 3265 \| HRAS \| DISEASES 6868 \| ADAM17 \| DISEASES 947 \| CD34 \| DISEASES 836 \| CASP3 \| DISEASES 92369 \| SPSB4 \| DISEASES 84868 \| HAVCR2 \| DISEASES 924 \| CD7 \| DISEASES 4778 \| NFE2 \| DISEASES 23262 \| PPIP5K2 \| DISEASES 4179 \| CD46 \| DISEASES 354 \| KLK3 \| DISEASES 3078 \| CFHR1 \| DISEASES 998 \| CDC42 \| DISEASES 2629 \| GBA \| DISEASES 30835 \| CD209 \| DISEASES 7298 \| TYMS \| DISEASES 1776 \| DNASE1L3 \| DISEASES 10332 \| CLEC4M \| DISEASES 1604 \| CD55 \| DISEASES 8225 \| GTPBP6 \| DISEASES 57381 \| RHOJ \| DISEASES 9377 \| COX5A \| DISEASES 10956 \| OS9 \| DISEASES 4684 \| NCAM1 \| DISEASES 23621 \| BACE1 \| DISEASES 27319 \| BHLHE22 \| DISEASES 2814 \| GP5 \| DISEASES 9322 \| TRIP10 \| DISEASES 54556 \| ING3 \| DISEASES 811 \| CALR \| DISEASES 6888 \| TALDO1 \| DISEASES 2149 \| F2R \| DISEASES 9920 \| KBTBD11 \| DISEASES 5345 \| SERPINF2 \| DISEASES 3039 \| HBA1 \| DISEASES 951 \| CD37 \| DISEASES 56984 \| PSMG2 \| DISEASES 5663 \| PSEN1 \| DISEASES 3052 \| HCCS \| DISEASES 161882 \| ZFPM1 \| DISEASES 6097 \| RORC \| DISEASES 4094 \| MAF \| DISEASES 7433 \| VIPR1 \| DISEASES 1435 \| CSF1 \| DISEASES 339390 \| CLEC4G \| DISEASES 79969 \| ATAT1 \| DISEASES 3563 \| IL3RA \| DISEASES 84876 \| ORAI1 \| DISEASES 10614 \| HEXIM1 \| DISEASES 8303 \| SNN \| DISEASES 2811 \| GP1BA \| DISEASES 389119 \| FAM212A \| DISEASES 23542 \| MAPK8IP2 \| DISEASES 79680 \| C22orf29 \| DISEASES 6401 \| SELE \| DISEASES 6007 \| RHD \| DISEASES 3418 \| IDH2 \| DISEASES 942 \| CD86 \| DISEASES 23545 \| ATP6V0A2 \| DISEASES 285525 \| YIPF7 \| DISEASES 9939 \| RBM8A \| DISEASES 3916 \| LAMP1 \| DISEASES 3043 \| HBB \| DISEASES 2152 \| F3 \| DISEASES 22821 \| RASA3 \| DISEASES 81608 \| FIP1L1 \| DISEASES 112744 \| IL17F \| DISEASES 5873 \| RAB27A \| DISEASES 143098 \| MPP7 \| DISEASES 1576 \| CYP3A4 \| DISEASES 3363 \| HTR7 \| DISEASES 23583 \| SMUG1 \| DISEASES 203068 \| TUBB \| DISEASES 2290 \| FOXG1 \| DISEASES 2885 \| GRB2 \| DISEASES 4602 \| MYB \| DISEASES 966 \| CD59 \| DISEASES 123228 \| SENP8 \| DISEASES 5781 \| PTPN11 \| DISEASES 113675 \| SDSL \| DISEASES 29087 \| THYN1 \| DISEASES 2804 \| GOLGB1 \| DISEASES 51393 \| TRPV2 \| DISEASES 921 \| CD5 \| DISEASES 3716 \| JAK1 \| DISEASES 3605 \| IL17A \| DISEASES 53827 \| FXYD5 \| DISEASES 8328 \| GFI1B \| DISEASES 7975 \| MAFK \| DISEASES 23764 \| MAFF \| DISEASES 2624 \| GATA2 \| DISEASES 3767 \| KCNJ11 \| DISEASES 1399 \| CRKL \| DISEASES 65992 \| DDRGK1 \| DISEASES 2534 \| FYN \| DISEASES 204 \| AK2 \| DISEASES 3792 \| KEL \| DISEASES 51287 \| COA4 \| DISEASES 4698 \| NDUFA5 \| DISEASES 3240 \| HP \| DISEASES 140885 \| SIRPA \| DISEASES 51155 \| HN1 \| DISEASES 26019 \| UPF2 \| DISEASES 2224 \| FDPS \| DISEASES 3683 \| ITGAL \| DISEASES 5169 \| ENPP3 \| DISEASES 55621 \| TRMT1 \| DISEASES 4097 \| MAFG \| DISEASES 8692 \| HYAL2 \| DISEASES 6714 \| SRC \| DISEASES 2213 \| FCGR2B \| DISEASES 2526 \| FUT4 \| DISEASES 56980 \| PRDM10 \| DISEASES 9332 \| CD163 \| DISEASES 5336 \| PLCG2 \| DISEASES 7456 \| WIPF1 \| DISEASES 6427 \| SRSF2 \| DISEASES 7037 \| TFRC \| DISEASES 6693 \| SPN \| DISEASES 2157 \| F8 \| DISEASES 4311 \| MME \| DISEASES 54106 \| TLR9 \| DISEASES 2993 \| GYPA \| DISEASES 6772 \| STAT1 \| DISEASES 7150 \| TOP1 \| DISEASES 2475 \| MTOR \| DISEASES 23038 \| WDTC1 \| DISEASES 9898 \| UBAP2L \| DISEASES 961 \| CD47 \| DISEASES 28514 \| DLL1 \| DISEASES 142 \| PARP1 \| DISEASES 3664 \| IRF6 \| DISEASES 1378 \| CR1 \| DISEASES 1380 \| CR2 \| DISEASES 722 \| C4BPA \| DISEASES 5788 \| PTPRC \| DISEASES 10878 \| CFHR3 \| DISEASES 3075 \| CFH \| DISEASES 64407 \| RGS18 \| DISEASES 5743 \| PTGS2 \| DISEASES 462 \| SERPINC1 \| DISEASES 8876 \| VNN1 \| DISEASES 2214 \| FCGR3A \| DISEASES 911 \| CD1C \| DISEASES 3713 \| IVL \| DISEASES 7390 \| UROS \| DISEASES 2209 \| FCGR1A \| DISEASES 914 \| CD2 \| DISEASES 4893 \| NRAS \| DISEASES 1736 \| DKC1 \| DISEASES 257 \| ALX3 \| DISEASES 2316 \| FLNA \| DISEASES 1806 \| DPYD \| DISEASES 5586 \| PKN2 \| DISEASES 1038 \| CDR1 \| DISEASES 60495 \| HPSE2 \| DISEASES 959 \| CD40LG \| DISEASES 5688 \| PSMA7 \| DISEASES 23421 \| ITGB3BP \| DISEASES 1791 \| DNTT \| DISEASES 3725 \| JUN \| DISEASES 11093 \| ADAMTS13 \| DISEASES 5900 \| RALGDS \| DISEASES 7422 \| VEGFA \| DISEASES 958 \| CD40 \| DISEASES 25 \| ABL1 \| DISEASES 4352 \| MPL \| DISEASES 1678 \| TIMM8A \| DISEASES 1025 \| CDK9 \| DISEASES 5303 \| PIN4 \| DISEASES 2833 \| CXCR3 \| DISEASES 7099 \| TLR4 \| DISEASES 51230 \| PHF20 \| DISEASES 1043 \| CD52 \| DISEASES 7357 \| UGCG \| DISEASES 978 \| CDA \| DISEASES 65110 \| UPF3A \| DISEASES 2159 \| F10 \| DISEASES 2155 \| F7 \| DISEASES 171023 \| ASXL1 \| DISEASES 6850 \| SYK \| DISEASES 80739 \| C6orf25 \| DISEASES 3055 \| HCK \| DISEASES 10673 \| TNFSF13B \| DISEASES 84930 \| MASTL \| DISEASES 22852 \| ANKRD26 \| DISEASES 50943 \| FOXP3 \| DISEASES 23590 \| PDSS1 \| DISEASES 7133 \| TNFRSF1B \| DISEASES 778 \| CACNA1F \| DISEASES 1041 \| CDSN \| DISEASES 4524 \| MTHFR \| DISEASES 2623 \| GATA1 \| DISEASES 7454 \| WAS \| DISEASES 3105 \| HLA-A \| DISEASES 7056 \| THBD \| DISEASES 5568 \| PRKACG \| DISEASES 8718 \| TNFRSF25 \| DISEASES 122183 \| PRR20A \| DISEASES 8418 \| CMAHP \| DISEASES 127262 \| TPRG1L \| DISEASES 2625 \| GATA3 \| DISEASES 5251 \| PHEX \| DISEASES 2683 \| B4GALT1 \| DISEASES 3301 \| DNAJA1 \| DISEASES 23322 \| RPGRIP1L \| DISEASES 3559 \| IL2RA \| DISEASES 54790 \| TET2 \| DISEASES 3704 \| ITPA \| DISEASES 3440 \| IFNA2 \| DISEASES 3456 \| IFNB1 \| DISEASES 241 \| ALOX5AP \| DISEASES 3030 \| HADHA \| DISEASES 51284 \| TLR7 \| DISEASES 3717 \| JAK2 \| DISEASES 83650 \| SLC35G5 \| DISEASES 9037 \| SEMA5A \| DISEASES 7750 \| ZMYM2 \| DISEASES 238 \| ALK \| DISEASES 3681 \| ITGAD \| DISEASES 1130 \| LYST \| DISEASES 11325 \| DDX42 \| DISEASES 28227 \| PPP2R3B \| DISEASES 147906 \| DACT3 \| DISEASES 2054 \| STX2 \| DISEASES 84071 \| ARMC2 \| DISEASES 2113 \| ETS1 \| DISEASES 5091 \| PC \| DISEASES 87 \| ACTN1 \| DISEASES 3426 \| CFI \| DISEASES 2875 \| GPT \| DISEASES 685 \| BTC \| DISEASES 2919 \| CXCL1 \| DISEASES 174 \| AFP \| DISEASES 6387 \| CXCL12 \| DISEASES 91452 \| ACBD5 \| DISEASES 6843 \| VAMP1 \| DISEASES 2120 \| ETV6 \| DISEASES 2628 \| GATM \| DISEASES 8131 \| NPRL3 \| DISEASES 2812 \| GP1BB \| DISEASES 4685 \| NCAM2 \| DISEASES 2160 \| F11 \| DISEASES 728441 \| GGT2 \| DISEASES 7018 \| TF \| DISEASES 7852 \| CXCR4 \| DISEASES 1111 \| CHEK1 \| DISEASES 3112 \| HLA-DOB \| DISEASES 342618 \| SLFN14 \| DISEASES 389362 \| PSMG4 \| DISEASES 83700 \| JAM3 \| DISEASES 720 \| C4A \| DISEASES 2935 \| GSPT1 \| DISEASES 960 \| CD44 \| DISEASES 7124 \| TNF \| DISEASES 2313 \| FLI1 \| DISEASES 5795 \| PTPRJ \| DISEASES 7072 \| TIA1 \| DISEASES 4615 \| MYD88 \| DISEASES 197320 \| ZNF778 \| DISEASES 7086 \| TKT \| DISEASES 388372 \| CCL4L1 \| DISEASES 3612 \| IMPA1 \| DISEASES 3451 \| IFNA17 \| DISEASES 3586 \| IL10 \| DISEASES 54475 \| NLE1 \| DISEASES 23218 \| NBEAL2 \| DISEASES 865 \| CBFB \| DISEASES 54872 \| PIGG \| DISEASES 133396 \| IL31RA \| DISEASES 721 \| C4B \| DISEASES 629 \| CFB \| DISEASES 57620 \| STIM2 \| DISEASES 374308 \| PTCHD3 \| DISEASES 114803 \| MYSM1 \| DISEASES 30816 \| ERVW-1 \| DISEASES 131870 \| NUDT16 \| DISEASES 51428 \| DDX41 \| DISEASES 345778 \| MTX3 \| DISEASES 285782 \| CAGE1 \| DISEASES 26064 \| RAI14 \| DISEASES 2994 \| GYPB \| DISEASES 84727 \| SPSB2 \| DISEASES 4067 \| LYN \| DISEASES 54970 \| TTC12 \| DISEASES 4798 \| NFRKB \| DISEASES 930 \| CD19 \| DISEASES 1232 \| CCR3 \| DISEASES 3684 \| ITGAM \| DISEASES 8825 \| LIN7A \| DISEASES 9051 \| PSTPIP1 \| DISEASES 567 \| B2M \| DISEASES 7732 \| RNF112 \| DISEASES 51741 \| WWOX \| DISEASES 820 \| CAMP \| DISEASES 2323 \| FLT3LG \| DISEASES 246734 \| NPCDR1 \| DISEASES 6625 \| SNRNP70 \| DISEASES 100885789 \| IFNG-AS1 \| DISEASES 100630918 \| PARTICL \| DISEASES 677806 \| SNORA20 \| DISEASES
Locus	(Waiting for update.)

Disease ID	124
Disease	thrombocytopenia
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:209) HP:0001945 \| Fever \| 200 HP:0001903 \| Anemia \| 87 HP:0012115 \| Liver inflammation \| 34 HP:0001878 \| Haemolytic anaemia \| 34 HP:0001875 \| Neutropenia \| 29 HP:0001744 \| Splenomegaly \| 24 HP:0200123 \| Chronic liver inflammation \| 21 HP:0100806 \| Sepsis \| 18 HP:0001394 \| Hepatic cirrhosis \| 18 HP:0002725 \| Systemic lupus erythematosus \| 16 HP:0001971 \| Hypersplenism \| 14 HP:0001909 \| Leukemia \| 13 HP:0003256 \| Coagulopathy \| 12 HP:0001902 \| Giant platelets \| 12 HP:0002863 \| Myelodysplastic syndrome \| 10 HP:0001937 \| Microangiopathic hemolytic anemia \| 9 HP:0001892 \| Bleeding diathesis \| 9 HP:0000979 \| Purpura \| 8 HP:0002664 \| Neoplasia \| 8 HP:0000083 \| Renal insufficiency \| 7 HP:0002239 \| Gastrointestinal hemorrhage \| 7 HP:0003003 \| Colon cancer \| 7 HP:0005537 \| Small platelet size \| 7 HP:0002584 \| Intestinal hemorrhage \| 7 HP:0001882 \| Decreased blood leukocyte number \| 7 HP:0011877 \| Increased mean platelet volume \| 6 HP:0002170 \| Intracranial hemorrhage \| 6 HP:0001876 \| Low blood cell count \| 6 HP:0001973 \| Autoimmune thrombocytopenia \| 6 HP:0001890 \| Autoimmune hemolytic anemia \| 5 HP:0001974 \| Leukocytosis \| 5 HP:0000822 \| Hypertension \| 4 HP:0002204 \| Pulmonary embolism \| 4 HP:0001409 \| Portal hypertension \| 4 HP:0002090 \| Pneumonia \| 4 HP:0001894 \| Thrombocytosis \| 4 HP:0003613 \| Antiphospholipid antibodies \| 4 HP:0002249 \| Melena \| 4 HP:0005528 \| Bone marrow hypoplasia \| 4 HP:0002045 \| Abnormally low body temperature \| 4 HP:0002721 \| Immunodeficiency \| 4 HP:0005550 \| Chronic lymphatic leukemia \| 4 HP:0001891 \| Iron-deficiency anemia \| 3 HP:0100602 \| Pre-eclampsia \| 3 HP:0002665 \| Lymphoma \| 3 HP:0001399 \| Liver failure \| 3 HP:0002719 \| infections, recurrent \| 3 HP:0001895 \| Normochromic anemia \| 3 HP:0000421 \| Bloody nose \| 3 HP:0012234 \| Agranulocytosis \| 3 HP:0012531 \| Pain \| 3 HP:0012325 \| Chronic myelomonocytic leukemia \| 3 HP:0005521 \| Disseminated intravascular coagulation \| 3 HP:0100033 \| Tic disorder \| 3 HP:0001511 \| Prenatal onset growth retardation \| 3 HP:0002960 \| Autoimmune condition \| 3 HP:0002910 \| Elevated transaminases \| 3 HP:0001433 \| Enlarged liver and spleen \| 3 HP:0001297 \| Cerebral vascular events \| 3 HP:0002488 \| Acute leukemias \| 3 HP:0003281 \| Increased ferritin \| 3 HP:0001888 \| Lymphocytopenia \| 3 HP:0009829 \| Phocomelia \| 2 HP:0002240 \| Enlarged liver \| 2 HP:0001677 \| Coronary artery disease \| 2 HP:0002904 \| High blood bilirubin levels \| 2 HP:0000716 \| Depression \| 2 HP:0001907 \| Thromboembolic disease \| 2 HP:0003974 \| Absent ossification/absence of radius \| 2 HP:0100626 \| Chronic hepatic failure \| 2 HP:0012378 \| Fatigue \| 2 HP:0012393 \| Allergy \| 2 HP:0100280 \| Morbus Crohn \| 2 HP:0012311 \| High blood monocyte number \| 2 HP:0002608 \| Celiac disease \| 2 HP:0003326 \| Muscle pain \| 2 HP:0001643 \| Persistent ductus arteriosus \| 2 HP:0001981 \| Schistocytosis \| 2 HP:0000964 \| Eczema \| 2 HP:0001658 \| Myocardial infarction \| 2 HP:0030731 \| Carcinoma \| 2 HP:0002625 \| Blood clot in a deep vein \| 2 HP:0002900 \| Hypokalemia \| 2 HP:0001873 \| Low platelet count \| 2 HP:0011273 \| Unequal size of red blood cells \| 2 HP:0001919 \| Acute renal failure \| 2 HP:0005575 \| Hemolytic-uremic syndrome \| 2 HP:0009733 \| Glioma \| 2 HP:0003774 \| End-stage renal failure \| 2 HP:0000967 \| Petechiae \| 2 HP:0011874 \| Heparin-induced thrombocytopenia \| 2 HP:0001410 \| Decreased liver function \| 2 HP:0012126 \| Gastric cancer \| 2 HP:0000093 \| Proteinuria \| 2 HP:0008151 \| Prolonged prothrombin time \| 2 HP:0001901 \| Abnormally shaped erythrocytes \| 1 HP:0001695 \| Cardiac arrest \| 1 HP:0000952 \| Yellow skin \| 1 HP:0002653 \| Bone pain \| 1 HP:0001271 \| Polyneuropathy \| 1 HP:0005547 \| Myeloproliferative disorder \| 1 HP:0000103 \| Polyuria \| 1 HP:0012125 \| Prostate cancer \| 1 HP:0010972 \| Anemia of inadequate production \| 1 HP:0003075 \| Hypoproteinemia \| 1 HP:0000988 \| Exanthem \| 1 HP:0005202 \| Helicobacter pylori infection \| 1 HP:0100761 \| Visceral angiomatosis \| 1 HP:0001897 \| Normocytic anemia \| 1 HP:0000501 \| Glaucoma \| 1 HP:0040187 \| Neonatal sepsis \| 1 HP:0001048 \| Cavernous angioma \| 1 HP:0000505 \| Poor vision \| 1 HP:0430007 \| Symblepharon \| 1 HP:0001953 \| Diabetic ketosis \| 1 HP:0000155 \| Oral ulcer \| 1 HP:0011675 \| Arrhythmias \| 1 HP:0004818 \| Paroxysmal nocturnal hemoglobinuria \| 1 HP:0002901 \| Hypocalcemia \| 1 HP:0012329 \| Angioblastoma \| 1 HP:0001629 \| Ventricular septal defects \| 1 HP:0002076 \| Migraine headaches \| 1 HP:0100242 \| Sarcoma \| 1 HP:0002014 \| Diarrhea \| 1 HP:0011854 \| Hemoperitoneum \| 1 HP:0002613 \| Biliary cirrhosis \| 1 HP:0002716 \| Lymph node hyperplasia \| 1 HP:0100843 \| Glioblastoma \| 1 HP:0100614 \| Muscle inflammation \| 1 HP:0002633 \| Vasculitis \| 1 HP:0002018 \| Nausea \| 1 HP:0100279 \| Ulcerative colitis \| 1 HP:0002155 \| Increased triglycerides \| 1 HP:0000123 \| Nephritis \| 1 HP:0002669 \| Osteosarcoma \| 1 HP:0002013 \| Emesis \| 1 HP:0012539 \| Non-Hodgkin lymphoma \| 1 HP:0002315 \| Headaches \| 1 HP:0000790 \| Hematuria \| 1 HP:0001650 \| Valvular aortic stenosis \| 1 HP:0011974 \| Myelofibrosis \| 1 HP:0000407 \| sensorineural hearing loss \| 1 HP:0002878 \| Respiratory failure \| 1 HP:0000518 \| Cataract \| 1 HP:0004936 \| Blood clot in vein \| 1 HP:0200023 \| Priapism \| 1 HP:0000519 \| Cataracts, lenticular, bilateral \| 1 HP:0005110 \| Atrial fibrillation \| 1 HP:0002835 \| Aspiration \| 1 HP:0006721 \| Acute lymphocytic leukemia \| 1 HP:0000939 \| Osteoporosis \| 1 HP:0002098 \| Respiratory distress \| 1 HP:0001541 \| Ascites \| 1 HP:0000656 \| Ectropion \| 1 HP:0001510 \| Growth deficiency \| 1 HP:0012211 \| Renal functional abnormality \| 1 HP:0011674 \| Cardiac teratoma \| 1 HP:0004447 \| Poikilocytosis \| 1 HP:0004420 \| Arterial thrombosis \| 1 HP:0200119 \| Acute liver inflammation \| 1 HP:0003761 \| Calcinosis \| 1 HP:0030746 \| Intraventricular hemorrhage \| 1 HP:0001518 \| Small for gestational age \| 1 HP:0000488 \| Noninflammatory retina disease \| 1 HP:0003765 \| Psoriasis \| 1 HP:0002093 \| progressive respiratory failure \| 1 HP:0006775 \| Multiple myeloma \| 1 HP:0002615 \| Low blood pressure \| 1 HP:0001249 \| Mental retardation \| 1 HP:0001369 \| Arthritis \| 1 HP:0006530 \| Interstitial lung disease \| 1 HP:0001087 \| Childhood glaucoma \| 1 HP:0000969 \| Dropsy \| 1 HP:0002329 \| Drowsiness \| 1 HP:0011896 \| Subconjunctival hemorrhage \| 1 HP:0003565 \| Elevated sedimentation rate \| 1 HP:0002974 \| Fused forearm bones \| 1 HP:0001935 \| Microcytic anemia \| 1 HP:0001824 \| Weight loss \| 1 HP:0009792 \| Teratoma \| 1 HP:0012330 \| Pyelonephritis \| 1 HP:0005508 \| Waldenstrom macroglobulinemia \| 1 HP:0100724 \| Hypercoagulability \| 1 HP:0011419 \| Abruptio placentae \| 1 HP:0000924 \| Abnormality of the skeletal system \| 1 HP:0100598 \| Pulmonary oedema \| 1 HP:0002527 \| Falls \| 1 HP:0008071 \| Maternal hypertension \| 1 HP:0100570 \| Carcinoid tumor \| 1 HP:0008282 \| Unconjugated hyperbilirubinemia \| 1 HP:0002829 \| Arthralgias \| 1 HP:0006562 \| Viral hepatitis \| 1 HP:0001972 \| Macrocytic anemia \| 1 HP:0001402 \| Hepatocellular carcinoma \| 1 HP:0001993 \| Ketoacidosis \| 1 HP:0000846 \| Hypoadrenalism \| 1 HP:0001923 \| Reticulocytosis \| 1 HP:0004808 \| Acute myelogenous leukemia \| 1 HP:0004844 \| Coombs-positive hemolytic anemia \| 1 HP:0002140 \| Ischemic stroke \| 1 HP:0005520 \| Chronic disseminated intravascular coagulation \| 1 HP:0002383 \| Encephalitis \| 1 HP:0012189 \| Hodgkin disease \| 1 HP:0200058 \| Angiosarcoma \| 1 HP:0008207 \| Addison's disease \| 1 HP:0012191 \| B-cell lymphoma \| 1 HP:0003401 \| Paresthesia \| 1 HP:0000132 \| Hypermenorrhea \| 1 HP:0002908 \| Conjugated hyperbilirubinemia \| 1

Disease ID	124
Disease	thrombocytopenia
Manually Symptom	UMLS \| Name(Total Manually Symptoms:82) C2707258 \| infections C2697310 \| sarcoidosis C2364133 \| infection C2364050 \| hypothermia C2186532 \| liver disease C1962966 \| retinopathy C1962958 \| hematoma C1660219 \| analgesia C1623038 \| cirrhosis C1521999 \| acute myocardial infarction C1509147 \| histiocytoma C1508749 \| capillary fragility C1443043 \| myeloproliferative syndromes C1387528 \| acute hemolytic anemia C1384590 \| hemangiomatosis C1333817 \| giant hemangioma C1275974 \| splenic hamartoma C1275974 \| hamartoma of spleen C1268935 \| microangiopathic hemolytic anemia C1142517 \| lupus anticoagulant C1027109 \| scleroderma C0948824 \| hemorrhagic anemia C0948089 \| acute coronary syndrome C0917798 \| cerebral ischemia C0878643 \| epiphenomenon C0796110 \| w syndrome C0796095 \| c syndrome C0728731 \| prematurity C0685201 \| splenic hemangioma C0600502 \| hemostatic disorders C0398686 \| primary immunodeficiency C0346424 \| splenic angiosarcoma C0338575 \| sagittal sinus thrombosis C0334121 \| inflammatory myofibroblastic tumor C0282607 \| vascular tumors C0272412 \| splenic abscess C0267373 \| intestinal bleeding C0265053 \| lower extremity thrombophlebitis C0221025 \| kasabach-merritt syndrome C0221021 \| microangiopathic haemolytic anaemia C0206255 \| malaria C0152915 \| disseminated tuberculosis C0151945 \| cerebral vein thrombosis C0085669 \| acute leukemia C0085278 \| antiphospholipid syndrome C0042974 \| von willebrand's disease C0040156 \| thyrotoxicosis C0040053 \| thrombosis C0035021 \| relapsing fever C0034150 \| purpuras C0034150 \| purpura C0032285 \| pneumonia C0032001 \| pituitary apoplexy C0031256 \| petechiae C0029927 \| ovarian cyst C0029166 \| oral manifestations C0027051 \| myocardial infarction C0026848 \| myopathy C0026691 \| kawasaki disease C0023794 \| lipidosis C0023418 \| leukemia C0021051 \| immunodeficiency disorder C0021051 \| immunodeficiency C0020532 \| hypersplenism C0019693 \| hiv infection C0019618 \| histiocytosis C0019189 \| chronic hepatitis C0019101 \| hemorrhagic fever with renal syndrome C0019087 \| hemorrhagic diathesis C0019087 \| haemorrhagic diathesis C0019080 \| hemorrhage C0018916 \| hemangiomas C0018916 \| hemangioma C0017181 \| gastrointestinal hemorrhage C0010823 \| cmv infection C0006309 \| brucellosis C0005956 \| bone marrow disease C0005818 \| platelet disorders C0005818 \| blood platelet disorders C0005779 \| coagulopathy C0002879 \| acquired hemolytic anemia C0002878 \| hemolytic anemia
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:41) C0040053 \| thrombosis \| 41 C0009450 \| infection \| 34 C0002878 \| hemolytic anemia \| 30 C0019080 \| hemorrhage \| 24 C0023895 \| liver disease \| 22 C0019189 \| chronic hepatitis \| 21 C0023890 \| cirrhosis \| 18 C0024530 \| malaria \| 17 C0020532 \| hypersplenism \| 14 C0796095 \| c syndrome \| 14 C0023418 \| leukemia \| 13 C0005779 \| coagulopathy \| 12 C0221021 \| microangiopathic hemolytic anemia \| 9 C0021311 \| infections \| 8 C0034150 \| purpura \| 8 C0267373 \| intestinal bleeding \| 7 C0948089 \| acute coronary syndrome \| 5 C0020672 \| hypothermia \| 4 C0032285 \| pneumonia \| 4 C0085669 \| acute leukemia \| 3 C0085278 \| antiphospholipid syndrome \| 3 C0021051 \| immunodeficiency \| 3 C0398686 \| primary immunodeficiency \| 3 C0019087 \| hemorrhagic diathesis \| 2 C0006309 \| brucellosis \| 2 C0018916 \| hemangiomas \| 2 C0027051 \| myocardial infarction \| 2 C0031256 \| petechiae \| 2 C0221021 \| microangiopathic haemolytic anaemia \| 2 C0085240 \| lupus anticoagulant \| 1 C0021051 \| immunodeficiency disorder \| 1 C0728731 \| prematurity \| 1 C0036202 \| sarcoidosis \| 1 C0221025 \| kasabach-merritt syndrome \| 1 C0019101 \| hemorrhagic fever with renal syndrome \| 1 C0346424 \| splenic angiosarcoma \| 1 C0018944 \| hematoma \| 1 C0032001 \| pituitary apoplexy \| 1 C0035309 \| retinopathy \| 1 C0019693 \| hiv infection \| 1 C0010823 \| cmv infection \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:2)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs786205154	NA	2120	ETV6	umls:C0040034	CLINVAR	NA	0.24	NA	ETV6	12	11885921	AACAG	-
rs786205155	NA	2120	ETV6	umls:C0040034	CLINVAR	NA	0.24	NA	ETV6	12	11884481	T	C

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:2)
CHR	POS	SNPID	REF	ALT	ORI_SNPID	PMID	P_VALUE	P_VALUE_TEXT	OR/BETA	CI95_TEXT	GWAS_INITIAL_SAMPLE_SIZE	SUB_POPULATION	SUPER_POPULATION	GWAS_TRAIT	HPO_ID	HPO_TERM	DO_ID	DO_TERM	MESH_ID	MESH_TERM	EFO_ID	EFO_TERM	DOLITE_TERM	RISK_ALLELE	PUBLICATION_TYPE	AA	GENE_SYMBOL	TYPE	REFGENE
5	176842474	rs2731672	T	C	rs2731672	21546496	1.00E-06	FXII levels	NA	NA	70 children	NOPOP(70)	ALL(70)	NOPOP(70)	ALL(70)	Platelet function and related traits	HPOID:0011869	Abnormal platelet function	DOID:2218	DOID:3393	blood platelet disease	coronary artery disease	D013921	Thrombocytopenia	NA	NA	Vascular disease	Hemorrhagic disorder	Thrombocytosis
20	3381549	rs965469	T	C	rs965469	21703177	1.00E-09	IFN-related thrombocytopenia at wk 4	NA	NA	984 European ancestry with genotype 1 HCV; 201 African Americans ancestry with genotype 1 HCV; 99 Hispanics ancestry with genotype 1 HCV	African American(201)	European(984)	Hispanic(99)	ALL(1284)	HIS(99)	AFR(201)	EUR(984)	ALL(1284)	IFN-related cytopenia	HPOID:0001871	Abnormality of blood and blood-forming tissues	DOID:1588	DOID:1227	thrombocytopenia	neutropenia	D013921	Thrombocytopenia	EFOID:0004220

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:86)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0040034	amifostine	D004999	20537-88-6	thrombocytopenia	MESH:D013921	therapeutic	1333372
C0040034	aminocaproic acid	D015119	60-32-2	thrombocytopenia	MESH:D013921	marker/mechanism	6537999
C0040034	aminosalicylic acid	D010131	65-49-6	thrombocytopenia	MESH:D013921	marker/mechanism	5434719
C0040034	amitriptyline	D000639	50-48-6	thrombocytopenia	MESH:D013921	marker/mechanism	910638
C0040034	ampicillin	D000667	69-53-4	thrombocytopenia	MESH:D013921	marker/mechanism	5101527
C0040034	argatroban	C031942	74863-84-6	thrombocytopenia	MESH:D013921	therapeutic	11269422
C0040034	arsenic trioxide	C006632	1327-53-3	thrombocytopenia	MESH:D013921	marker/mechanism	17497326
C0040034	aspartame	D001218	22839-47-0	thrombocytopenia	MESH:D013921	marker/mechanism	17534100
C0040034	bivalirudin	C074619	128270-60-0	thrombocytopenia	MESH:D013921	therapeutic	16651880
C0040034	bleomycin	D001761	11056-06-7	thrombocytopenia	MESH:D013921	marker/mechanism	54212
C0040034	bortezomib	D000069286	-	thrombocytopenia	MESH:D013921	marker/mechanism	15738379
C0040034	busulfan	D002066	55-98-1	thrombocytopenia	MESH:D013921	marker/mechanism	16543071
C0040034	carbamazepine	D002220	298-46-4	thrombocytopenia	MESH:D013921	marker/mechanism	12897634
C0040034	carbimazole	D002231	22232-54-8	thrombocytopenia	MESH:D013921	marker/mechanism	10848805
C0040034	carmustine	D002330	154-93-8	thrombocytopenia	MESH:D013921	marker/mechanism	12494480
C0040034	cetirizine	D017332	83881-51-0	thrombocytopenia	MESH:D013921	marker/mechanism	17955500
C0040034	chloramphenicol	D002701	56-75-7	thrombocytopenia	MESH:D013921	marker/mechanism	6071896
C0040034	cladribine	D017338	4291-63-8	thrombocytopenia	MESH:D013921	marker/mechanism	12181031
C0040034	cimetidine	D002927	51481-61-9	thrombocytopenia	MESH:D013921	marker/mechanism	7427548
C0040034	ciprofloxacin	D002939	85721-33-1	thrombocytopenia	MESH:D013921	marker/mechanism	12022900
C0040034	colchicine	D003078	64-86-8	thrombocytopenia	MESH:D013921	marker/mechanism	16240705
C0040034	cyclophosphamide	D003520	50-18-0	thrombocytopenia	MESH:D013921	marker/mechanism	12406105
C0040034	cyclosporine	D016572	59865-13-3	thrombocytopenia	MESH:D013921	marker/mechanism	12469693
C0040034	cyclosporine	D016572	59865-13-3	thrombocytopenia	MESH:D013921	therapeutic	10410193
C0040034	cisplatin	D002945	15663-27-1	thrombocytopenia	MESH:D013921	marker/mechanism	11135224
C0040034	cisplatin	D002945	15663-27-1	thrombocytopenia	MESH:D013921	therapeutic	24158386
C0040034	diclofenac	D004008	15307-86-5	thrombocytopenia	MESH:D013921	marker/mechanism	11051389
C0040034	epirubicin	D015251	56420-45-2	thrombocytopenia	MESH:D013921	marker/mechanism	11557123
C0040034	eptifibatide	C086648	-	thrombocytopenia	MESH:D013921	marker/mechanism	17008982
C0040034	ethambutol	D004977	74-55-5	thrombocytopenia	MESH:D013921	marker/mechanism	188103
C0040034	ethosuximide	D005013	77-67-8	thrombocytopenia	MESH:D013921	marker/mechanism	623072
C0040034	everolimus	D000068338	-	thrombocytopenia	MESH:D013921	marker/mechanism	10551636
C0040034	fenoprofen	D005279	31879-05-7	thrombocytopenia	MESH:D013921	marker/mechanism	6228839
C0040034	fluconazole	D015725	86386-73-4	thrombocytopenia	MESH:D013921	marker/mechanism	24459006
C0040034	fluorouracil	D005472	51-21-8	thrombocytopenia	MESH:D013921	marker/mechanism	12119460
C0040034	folic acid	D005492	59-30-3	thrombocytopenia	MESH:D013921	therapeutic	8958188
C0040034	leucovorin	D002955	1958/5/9	thrombocytopenia	MESH:D013921	marker/mechanism	12119460
C0040034	leucovorin	D002955	1958/5/9	thrombocytopenia	MESH:D013921	therapeutic	6607976
C0040034	gefitinib	C419708	184475-35-2	thrombocytopenia	MESH:D013921	marker/mechanism	15196742
C0040034	gemcitabine	C056507	103882-84-4	thrombocytopenia	MESH:D013921	marker/mechanism	10526274
C0040034	haloperidol	D006220	52-86-8	thrombocytopenia	MESH:D013921	marker/mechanism	9637888
C0040034	hydroxyurea	D006918	127-07-1	thrombocytopenia	MESH:D013921	marker/mechanism	12620292
C0040034	ifosfamide	D007069	3778-73-2	thrombocytopenia	MESH:D013921	marker/mechanism	15150579
C0040034	indomethacin	D007213	53-86-1	thrombocytopenia	MESH:D013921	marker/mechanism	12632374
C0040034	lenalidomide	C467567	-	thrombocytopenia	MESH:D013921	marker/mechanism	17723971
C0040034	lepirudin	C083544	-	thrombocytopenia	MESH:D013921	therapeutic	15333046
C0040034	linezolid	D000069349	-	thrombocytopenia	MESH:D013921	marker/mechanism	11794421
C0040034	mefloquine	D015767	53230-10-7	thrombocytopenia	MESH:D013921	marker/mechanism	8161647
C0040034	melphalan	D008558	148-82-3	thrombocytopenia	MESH:D013921	marker/mechanism	10656432
C0040034	meprobamate	D008620	57-53-4	thrombocytopenia	MESH:D013921	marker/mechanism	5092569
C0040034	methotrexate	D008727	1959/5/2	thrombocytopenia	MESH:D013921	marker/mechanism	16246977
C0040034	mitomycin	D016685	1950/7/7	thrombocytopenia	MESH:D013921	marker/mechanism	12119460
C0040034	mitoxantrone	D008942	65271-80-9	thrombocytopenia	MESH:D013921	marker/mechanism	10597740
C0040034	omeprazole	D009853	73590-58-6	thrombocytopenia	MESH:D013921	marker/mechanism	9695674
C0040034	oxaliplatin	C030110	-	thrombocytopenia	MESH:D013921	marker/mechanism	15274380
C0040034	paclitaxel	D017239	-	thrombocytopenia	MESH:D013921	marker/mechanism	10037178
C0040034	paclitaxel	D017239	-	thrombocytopenia	MESH:D013921	therapeutic	16332718
C0040034	pefloxacin	D015366	70458-92-3	thrombocytopenia	MESH:D013921	marker/mechanism	2258351
C0040034	pegfilgrastim	C455861	-	thrombocytopenia	MESH:D013921	marker/mechanism	20547415
C0040034	peginterferon alfa-2b	C417083	-	thrombocytopenia	MESH:D013921	marker/mechanism	16637862
C0040034	phenytoin	D010672	57-41-0	thrombocytopenia	MESH:D013921	marker/mechanism	1147459
C0040034	propranolol	D011433	525-66-6	thrombocytopenia	MESH:D013921	therapeutic	11871761
C0040034	propylthiouracil	D011441	51-52-5	thrombocytopenia	MESH:D013921	marker/mechanism	566489
C0040034	pyrazinamide	D011718	98-96-4	thrombocytopenia	MESH:D013921	marker/mechanism	5434719
C0040034	quinine	D011803	130-95-0	thrombocytopenia	MESH:D013921	marker/mechanism	10474732
C0040034	raltitrexed	C068874	-	thrombocytopenia	MESH:D013921	marker/mechanism	11528249
C0040034	ribavirin	D012254	36791-04-5	thrombocytopenia	MESH:D013921	marker/mechanism	15081101
C0040034	rifampin	D012293	13292-46-1	thrombocytopenia	MESH:D013921	marker/mechanism	11798598
C0040034	sirolimus	D020123	53123-88-9	thrombocytopenia	MESH:D013921	marker/mechanism	10221490
C0040034	streptozocin	D013311	18883-66-4	thrombocytopenia	MESH:D013921	marker/mechanism	135666
C0040034	tacrolimus	D016559	109581-93-3	thrombocytopenia	MESH:D013921	marker/mechanism	12753543
C0040034	temozolomide	C047246	85622-93-1	thrombocytopenia	MESH:D013921	marker/mechanism	17108062
C0040034	thalidomide	D013792	50-35-1	thrombocytopenia	MESH:D013921	marker/mechanism	24928523
C0040034	thiotepa	D013852	52-24-4	thrombocytopenia	MESH:D013921	marker/mechanism	2121628
C0040034	ticlopidine	D013988	55142-85-3	thrombocytopenia	MESH:D013921	marker/mechanism	20031738
C0040034	tinidazole	D014011	19387-91-8	thrombocytopenia	MESH:D013921	marker/mechanism	7123
C0040034	valproic acid	D014635	99-66-1	thrombocytopenia	MESH:D013921	marker/mechanism	10698845
C0040034	vancomycin	D014640	1404-90-6	thrombocytopenia	MESH:D013921	marker/mechanism	14520145
C0040034	vinblastine	D014747	865-21-4	thrombocytopenia	MESH:D013921	marker/mechanism	54212
C0040034	vincristine	D014750	-	thrombocytopenia	MESH:D013921	marker/mechanism	11305414
C0040034	vincristine	D014750	-	thrombocytopenia	MESH:D013921	therapeutic	2981498
C0040034	vindesine	D014751	53643-48-4	thrombocytopenia	MESH:D013921	marker/mechanism	3857971
C0040034	vinorelbine	C030852	71486-22-1	thrombocytopenia	MESH:D013921	marker/mechanism	10526274
C0040034	vorinostat	C111237	-	thrombocytopenia	MESH:D013921	marker/mechanism	18854394
C0040034	zidovudine	D015215	30516-87-1	thrombocytopenia	MESH:D013921	marker/mechanism	18240862
C0040034	zidovudine	D015215	30516-87-1	thrombocytopenia	MESH:D013921	therapeutic	3190058

FDA approved drug and dosage information(Total Drugs:38)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D013921	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D013921	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D013921	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D013921	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D013921	zyvox	linezolid	400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D013921	zyvox	linezolid	200MG/100ML (2MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	No
MESH:D013921	zyvox	linezolid	100MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	Yes
MESH:D013921	zyvox	linezolid	400MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	TABLET;ORAL	Discontinued	None	Yes	No
MESH:D013921	zyvox	linezolid	200MG/100ML (2MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	No
MESH:D013921	zyvox	linezolid	100MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	Yes
MESH:D013921	busulfex	busulfan	6MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D013921	temodar	temozolomide	5MG	CAPSULE;ORAL	Prescription	AB	Yes	No
MESH:D013921	temodar	temozolomide	100MG/VIAL	POWDER;INTRAVENOUS	Prescription	None	Yes	Yes
MESH:D013921	cipro	ciprofloxacin	400MG/40ML (10MG/ML)	INJECTABLE;INJECTION	Discontinued	None	Yes	No
MESH:D013921	cipro	ciprofloxacin	250MG/5ML	FOR SUSPENSION;ORAL	Prescription	AB	Yes	No
MESH:D013921	rapamune	sirolimus	1MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
MESH:D013921	rapamune	sirolimus	1MG	TABLET;ORAL	Prescription	AB	Yes	No
MESH:D013921	eloxatin	oxaliplatin	50MG/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	INJECTABLE;IV (INFUSION)	Discontinued	None	Yes	No
MESH:D013921	eloxatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D013921	oxaliplatin	oxaliplatin	50MG/10ML (5MG/ML)	INJECTABLE;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D013921	argatroban	argatroban	250MG/2.5ML (100MG/ML)	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D013921	argatroban	argatroban	250MG/250ML	INJECTABLE; INJECTION	None (Tentative Approval)	None	No	No
MESH:D013921	argatroban	argatroban	250MG/2.5ML (100MG/ML)	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D013921	argatroban	argatroban	250MG/250ML	INJECTABLE; INJECTION	None (Tentative Approval)	None	No	No
MESH:D013921	retrovir	zidovudine	100MG	CAPSULE;ORAL	Prescription	AB	Yes	Yes
MESH:D013921	retrovir	zidovudine	100MG	CAPSULE;ORAL	Prescription	AB	Yes	Yes
MESH:D013921	retrovir	zidovudine	50MG/5ML	SYRUP;ORAL	Prescription	AA	Yes	Yes
MESH:D013921	retrovir	zidovudine	50MG/5ML	SYRUP;ORAL	Prescription	AA	Yes	Yes
MESH:D013921	retrovir	zidovudine	10MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D013921	retrovir	zidovudine	10MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D013921	retrovir	zidovudine	200MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	retrovir	zidovudine	200MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D013921	afinitor	everolimus	5MG	TABLET;ORAL	Prescription	None	Yes	No
MESH:D013921	velcade	bortezomib	3.5MG/VIAL	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	Prescription	None	Yes	Yes

FDA labeling changes(Total Drugs:38)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D013921	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D013921	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D013921	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D013921	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D013921	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	12/19/2002	zyvox	linezolid	Nosocomial pneumonia, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and vancomycin-resistant infections caused by susceptible strains	Extended age range down to birth for nosocomial pneumonia, community-acquired pneumonia, complicated skin and skin structure infections and vancomycin-resistant infections. Safety and efficacy extrapolated from studies in adults and supported by PK and comparator-controlled studies in patients from birth to 11 years Extended age range down to 5 years of age for uncomplicated skin and skin structure infections based upon a comparator-controlled study in 5 to 17 year olds Clearance of linezolid varies as a function of age; As age of pediatric patients increases, clearance gradually decreases, and by adolescence mean clearance values approach those observed in adults Pediatric patients exhibit wider variability in clearance and systemic exposure (AUC) compared with adults New every 8 hours dosing regimen for pediatric patients birth to 11 years of age and every 12 hours dosing regimen for pediatric patients 12 years and older Information on PK parameters, AE profile, laboratory changes, dosing, and clinical studies	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	12/5/2005	zyvox	linezolid	Central nervous system infections	PK data in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) concentrations; therapeutic concentrations were not consistently achieved or maintained in the CSF Use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended Additional information on efficacy in pediatric patients with infectious vancomycin-resistant Enterococcus faecium	Labeling	B	-	-	-	Pfizer	11/2/2005	FALSE'
MESH:D013921	01/13/2003	busulfex	busulfan	Part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases	The population pharmacokinetic estimates of busulfan for clearance and volume of distribution were determined in an open-label, uncontrolled PK study in 24 pediatric patients 5 months to 16 years who received busulfan as part of a conditioning regimen administered prior to hematopoietic progenitor cell transplantation for a variety of malignant hematologic or non-malignant diseases Suggested dosing regimen	Labeling	B	-	-	-	Orphan Medical	12/3/2002	FALSE'
MESH:D013921	11/3/2003	temodar	temozolomide	Recurrent CNS tumors	Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults	Labeling	B	-	-	-	Schering	11/20/2002	FALSE'
MESH:D013921	11/3/2003	temodar	temozolomide	Recurrent CNS tumors	Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults	Labeling	B	-	-	-	Schering	11/20/2002	FALSE'
MESH:D013921	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D013921	03/25/2004	cipro	ciprofloxacin	Complicated UTI and pyelonephritis	Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively	Labeling	B	-	-	-	Bayer	12/18/2003	FALSE'
MESH:D013921	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D013921	11/3/2005	rapamune	sirolimus	Prophylaxis of organ rejection in patients undergoing renal transplants	Safety and efficacy established in children 13 years or older judged to be at low to moderate immunologic risk Safety was assessed in a controlled clinical trial in pediatric (	Labeling	B	-	-	-	Wyeth	11/17/2004	FALSE'
MESH:D013921	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D013921	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D013921	10/1/2007	eloxatin	oxaliplatin	Solid tumors	The effectiveness of oxaliplatin in children has not been established No significant activity observed in 2 Phase I and 2 Phase II trials in 159 patients ages 7 months to 22 years with solid tumors Information on clinical studies and AEs	Labeling	B	-	-	-	Sanofi-Aventis	09/27/2006	FALSE'
MESH:D013921	5/5/2008	argatroban	argatroban	Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis	Safety and effectiveness, including the appropriate anticoagulation goals and duration of therapy, have not been established in pediatric patients Population PK/PD analysis of sparse data in 15 seriously ill pediatric patients ages	Labeling	-	-	B, P	-	Encysive	-	FALSE'
MESH:D013921	5/5/2008	argatroban	argatroban	Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis	Safety and effectiveness, including the appropriate anticoagulation goals and duration of therapy, have not been established in pediatric patients Population PK/PD analysis of sparse data in 15 seriously ill pediatric patients ages	Labeling	-	-	B, P	-	Encysive	-	FALSE'
MESH:D013921	5/5/2008	argatroban	argatroban	Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis	Safety and effectiveness, including the appropriate anticoagulation goals and duration of therapy, have not been established in pediatric patients Population PK/PD analysis of sparse data in 15 seriously ill pediatric patients ages	Labeling	-	-	B, P	-	Encysive	-	FALSE'
MESH:D013921	5/5/2008	argatroban	argatroban	Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis	Safety and effectiveness, including the appropriate anticoagulation goals and duration of therapy, have not been established in pediatric patients Population PK/PD analysis of sparse data in 15 seriously ill pediatric patients ages	Labeling	-	-	B, P	-	Encysive	-	FALSE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	09/19/2008	retrovir syrup, capsules and tablets	zidovudine	Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection	Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	09/19/2008	retrovir syrup, capsules and tablets	zidovudine	Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection	Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D013921	10/29/2010	afinitor	everolimus	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis	Approved for treatment of patients with SEGA associated with TS An open-label, single-arm safety and efficacy trial was conducted in 28 patients 3-34 years with SEGA associated with TS Afinitor has not been studied in patients with SEGA < 3 years of ageMost common adverse reactions (incidence e30%) were stomatitis, upper respiratory tract infection, sinusitis, otitis media, and pyrexiaDose reduction and/or treatment interruption may be needed to manage adverse drug reactions Information on starting dose, therapeutic drug monitoring, clinical trial, and adverse reactions New indication	Labeling	B	-	-	-	Novartis	-	FALSE'
MESH:D013921	09/14/2015	velcade	bortezomib	Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)	Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed	Labeling	B	-	-	-	Millennium Pharmaceuticals, Inc.	-	FALSE